EXHIBIT 99.1 On October 1, 2020 (the Closing Date), Xtant Medical Holdings, Inc. (the Company) exchanged shares of its common stock (the Common Stock) for approximately $40.8 million of the aggregate outstanding principal amount of the loans (as...Second Amended and Restated Credit Agreement • October 5th, 2020 • Xtant Medical Holdings, Inc. • Biological products, (no disgnostic substances)
On October 1, 2020 (the Closing Date), Xtant Medical Holdings, Inc. (the Company) exchanged shares of its common stock (the Common Stock) for approximately $40.8 million of the aggregate outstanding principal amount of the loans (as defined in the Second Amended and Restated Credit Agreement, dated as of March 29, 2019, by and among the Company, Bacterin International, Inc., Xtant Medical, Inc., X-spine Systems, Inc., and OrbiMed Royalty Opportunities II, LP (ORO II) and ROS Acquisition Offshore LP (ROS Acquisition and collectively with ORO II, the Lenders) (as amended, restated and otherwise modified prior to the date hereof, Second A&R Credit Agreement) outstanding under the Second A&R Credit Agreement, as well as, without duplication, approximately $21.1 million of the outstanding amount of PIK Interest (as defined in the Second A&R Credit Agreement) (such loans and PIK Interest, the Exchanging Loans), plus all other accrued and unpaid interest on the Exchanging Loans outstanding as
